Manage the complexities of osteoporosis care by understanding the latest advancements in genetic risk assessment. Antiresorptive medications, primarily bisphosphonates and denosumab, remain the standard of care for preventing bone fractures in patients suffering from osteoporosis or bone metastases. However, a rare but severe side effect known as medication-related osteonecrosis of the jaw (MRONJ) causes significant anxiety, leading some patients to refuse essential treatment. Recent research conducted at Semmelweis University in Hungary has made substantial progress in identifying the genetic risk factors associated with this condition, an achievement that rightfully earned the Semmelweis Innovation Award.
Understanding the Challenges of Modern Osteoporosis Treatment
Osteoporosis represents a major public health challenge globally, characterized by decreased bone density and an increased susceptibility to fractures. The individual burden of these fractures is profound, often resulting in chronic pain, disability, and a loss of independence. In older populations, the forced inactivity following a fracture markedly increases mortality rates. Furthermore, bone metastases frequently complicate advanced stages of breast and prostate cancers, necessitating aggressive skeletal management.
To combat these issues, physicians routinely prescribe antiresorptive therapies. These drugs effectively slow down bone loss by inhibiting osteoclasts, the cells responsible for bone resorption. While highly effective for the vast majority of patients, these medications carry a black-box warning for MRONJ. This condition involves the exposure and death of jawbone tissue, leading to severe pain, dental complications, tooth loss, and significant difficulties with eating. Because MRONJ drastically impairs a patient’s quality of life, the fear of developing it often outweighs the statistical risk, prompting patients to decline or discontinue their osteoporosis treatment. Finding a way to accurately predict this risk has become a critical priority in rheumatology and oncology.
Schedule a free consultation to learn more about advanced osteoporosis management.
Identifying Genetic Risk Factors for Osteonecrosis of the Jaw
MRONJ is relatively rare among osteoporosis patients, affecting only a fraction of a percent. However, the incidence rate jumps significantly—sometimes reaching several percent—in cancer patients receiving high-dose antiresorptive therapy for bone metastases. While clinical risk factors such as tooth extractions, poor oral hygiene, and prolonged steroid use are well-documented, they do not fully explain why one patient develops the condition while another on the exact same regimen does not. This variability points strongly to underlying genetic risk factors.
Recognizing this gap in clinical knowledge, researchers set out to isolate specific genetic markers that could predispose individuals to MRONJ. The objective was to move away from a one-size-fits-all approach and toward a precision medicine model. By identifying patients who are genetically susceptible to the side effect, clinicians could theoretically make better-informed decisions, either by selecting alternative therapies or by implementing heightened preventive dental measures before initiating treatment.
The Role of the SIRT1 Gene
Focus shifted to the Sirtuin 1 (SIRT1) gene, which plays a crucial role in cellular regulation, including inflammation, apoptosis, and stress resistance. The hypothesis was that variations in this gene might affect how jawbone tissue responds to the biological changes induced by antiresorptive drugs. Analyzing the SIRT1 gene provided a targeted approach after initial broad, genome-wide analyses pointed toward its significance.
Have questions about genetic testing in medical care? Write to us!
How Semmelweis University Researchers Analyzed the SIRT1 Gene
The award-winning study was led by Dr. Bence Bojtor, a resident in internal medicine at Semmelweis University’s Department of Internal Medicine and Oncology. What makes this research particularly notable is that Dr. Bojtor initiated the project during his fourth year of medical school, continuing it through the university’s rigorous MD-PhD program under the mentorship of Professor Dr. Péter Lakatos and Dr. János Kósa, Head of the Molecular Diagnostics Laboratory.
To ensure robust, globally relevant data, the research team collaborated with the University of Florida. The study initially utilized a broad genome-wide genetic analysis involving approximately 60 patients diagnosed with osteonecrosis of the jaw. Following these promising initial results, the team conducted a focused investigation specifically on the SIRT1 gene, drawing genetic samples from patients treated at Semmelweis University’s Department of Oro-Maxillofacial Surgery and Stomatology.
Collecting data on rare diseases presents distinct statistical challenges. Because MRONJ is uncommon, amassing a large cohort requires extensive multi-departmental and international cooperation. By combining forces, the researchers successfully gathered 64 high-quality genetic samples from patients suffering from this rare disease. The genetic testing was performed using standard blood samples processed in the department’s laboratory, with results typically available within a few weeks.
Innovative Statistical Methodology
To analyze the heterogeneous data effectively, the team employed a novel statistical method developed by Dr. János Podani, a Professor of Biology at Eötvös Loránd University in Hungary. This advanced methodology allowed the researchers to simultaneously analyze a diverse statistical population, accounting for various confounding variables that typically complicate rare-disease research. This rigorous analytical approach lent significant weight to the study’s final conclusions.
Implications for Personalized Medicine in Hungary and Beyond
The findings from the Semmelweis University study clearly demonstrate the importance of personalized medicine in modern therapeutics. The researchers examined a minor genetic variation within the SIRT1 gene, comparing its frequency in patients with MRONJ against a healthy control population. They discovered that a specific variant—referred to as the beneficial allele—occurs less frequently in patients with osteonecrosis and more frequently in healthy individuals.
This correlation suggests that the presence of this beneficial allele provides a degree of protection against the development of MRONJ. Importantly, carrying this genetic trait does not guarantee absolute immunity; rather, it statistically lowers the chance of disease onset. Furthermore, the researchers tracked patient outcomes following dental treatments for osteonecrosis. They found that patients possessing the beneficial allele experienced a lower rate of disease recurrence. Therefore, this specific genetic marker is associated with both a reduced risk of developing the condition and a more favorable clinical outcome if treatment is required.
Explore our related articles for further reading on personalized medicine.
Future Directions for Osteoporosis Care and the Innovation Award
Winning the Semmelweis Innovation Award highlights the practical clinical potential of this research. The immediate goal is to facilitate widespread access to genetic testing prior to the initiation of antiresorptive treatment. This preemptive screening is especially critical for cancer patients, whose risk of developing MRONJ is roughly ten times higher than that of non-cancer patients receiving osteoporosis treatment. A reliable genetic risk assessment test would empower patients and physicians to weigh the benefits and risks of antiresorptive therapy with concrete, individualized data rather than broad statistical probabilities.
Looking forward, the research team is actively expanding the database of Hungarian patients with MRONJ to further validate these findings. They have also begun measuring the actual levels of the SIRT1 protein in patients’ blood—a novel approach that could yield even faster clinical insights. Preliminary data indicates that SIRT1 protein levels tend to be lower in patients who develop osteonecrosis. This biochemical discovery opens the door to a long-term therapeutic goal: developing pharmaceutical drugs that promote SIRT1 protein activation, potentially offering a way to protect at-risk patients at the molecular level.
While the current dataset combines Hungarian and American populations through the collaboration with the University of Florida, researchers emphasize the need for global expansion. Studying populations of other nationalities and racial groups will determine if the SIRT1 gene’s protective effect is universal or varies by demographic. As the boundaries of genetic research continue to expand, institutions like Semmelweis University remain at the forefront, translating complex molecular biology into actionable, life-improving clinical strategies.
Submit your application today to join leading medical research programs.
